Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Sungkyunkwan University School of Medicine, Samsung Medical Center

2 abstracts

Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Indiana Blood and & Marrow Transplantation, Franciscan Health, Karmanos Cancer Institute, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Sungkyunkwan University School of Medicine, Samsung Medical Center,